Trials / Completed
CompletedNCT02846324
Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPF
A Phase II Randomized, Placebo-Controlled Study of GBT440 to Evaluate the Safety, Tolerability, Pharmacokinetics and Effect on Hypoxemia in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- Global Blood Therapeutics · Industry
- Sex
- All
- Age
- 45 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study is a randomized, double-blind, placebo-controlled trial in which eligible IPF subjects will be randomized to receive GBT440 or Placebo orally daily.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GBT440 | Capsules which contain GBT440 drug substance in Swedish orange |
| DRUG | Placebo | Placebo capsules |
Timeline
- Start date
- 2016-06-01
- Primary completion
- 2017-09-01
- Completion
- 2017-11-01
- First posted
- 2016-07-27
- Last updated
- 2020-10-20
- Results posted
- 2020-09-22
Locations
12 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02846324. Inclusion in this directory is not an endorsement.